Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy

Hepatology

Volumn 59, Issue 3, 2014, Pages 1073-1083

  Rockey, Don C ^a   Vierling, John M ^b   Mantry, Parvez ^c   Ghabril, Marwan ^d   Brown, Robert S ^e   Alexeeva, Olga ^f   Zupanets, Igor A ^g   Grinevich, Vladimir ^h   Baranovsky, Andrey ⁱ   Dudar, Larysa ^j   Fadieienko, Galyna ^k   Kharchenko, Nataliya ^l   Klaryts'ka, Iryna ^m   Morozov, Vyacheslav ⁿ   Grewal, Priya ^o   Mccashland, Timothy ^p   Reddy, K Gautham ^q   Reddy, K Rajender ^r   Syplyviy, Vasyl ^s   Bass, Nathan M ^t   Dickinson, Klara ^u   Norris, Catherine ^u   Coakley, Dion ^u   Mokhtarani, Masoud ^u   Scharschmidt, Bruce F ^u   Ahmed, A ^v   Balart, L ^w   Berk, B ^x   Brown, K ^y   Frolov, A ^z   Howell, C ^aa   Khrustalev, O ^ab   Lucey, M ^ac   Maliakkal, B ^ad   Mendoza, A ^ae   O'Brien, C ^af   O'Shea, R ^ag   Porayko, M ^ah   Radchenko, V ^ai   Rahimi, R ^aj   Shah, N ^ak   Shetty, K ^al   Sigal, S ^am   Storozhakov, G ^an   Zucker, S ^ao   Tobias, H ^ap   Voigt, M ^aq   Weinman, S ^ar   Wolf, D ^as   Zhidkov, K ^at   Zvyagintseva, T ^au   more..

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c METHODIST DALLAS MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY   (United States)

^e NewYork Presbyterian Hospital   (United States)

^f Nizhny Novgorod Regional Hospital   (Russian Federation)

^g NATIONAL UNIVERSITY OF PHARMACY   (Ukraine)

^h S M KIROV MILITARY MEDICAL ACADEMY   (Russian Federation)

ⁱ St Petersburg City Hospital #31   (Russian Federation)

^j BOGOMOLETS NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^k Government Institution LTMalaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine   (Ukraine)

^l SHUPYK NATIONAL MEDICAL ACADEMY OF POSTGRADUATE EDUCATION   (Ukraine)

^m Crimean Republican Institution MO Semashko Clinical Hospital   (Ukraine)

ⁿ Medical Company Hepatolog Incorporated   (Russian Federation)

^o MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^q UNIVERSITY OF CHICAGO   (United States)

^r UNIVERSITY OF PENNSYLVANIA   (United States)

^s KHARKIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u Hyperion Therapeutics Inc   (United States)

^v STANFORD UNIVERSITY   (United States)

^w TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^x DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^y HENRY FORD HOSPITAL   (United States)

^z Togliatti City Clinical Hospital 1   (Russian Federation)

^aa UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^ab Yaroslavl Regional Clinical Hospital   (Russian Federation)

^ac UNIVERSITY OF WISCONSIN MADISON   (United States)

^ad UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^ae TAMPA GENERAL HOSPITAL   (United States)

^af UNIVERSITY OF MIAMI   (United States)

^ag LERNER RESEARCH INSTITUTE   (United States)

^ah VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^ai NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^aj UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^ak UNIVERSITY OF VIRGINIA   (United States)

^al GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^am NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^an PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^ao UNIVERSITY OF CINCINNATI   (United States)

^ap The Concord Medical Group   (United States)

^aq UNIVERSITY OF IOWA   (United States)

^ar UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^as NEW YORK MEDICAL COLLEGE   (United States)

^at City Hospital 26   (Russian Federation)

^au KHARKIV MEDICAL ACADEMY OF POSTGRADUATE EDUCATION   (Ukraine)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMMONIA; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLYCEROL PHENYLBUTYRATE; LACTULOSE; PLACEBO; RIFAXIMIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMMONIA BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEALTH CARE QUALITY; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMAN; INFECTION; INTERNATIONAL NORMALIZED RATIO; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; VOMITING; YOUNG ADULT;

ADULT; AGED; AMMONIA; DOUBLE-BLIND METHOD; FEMALE; GLUTAMINE; GLYCEROL; HEPATIC ENCEPHALOPATHY; HUMANS; HYPERAMMONEMIA; MALE; MIDDLE AGED; PHENYLBUTYRATES; TREATMENT OUTCOME; UREA; YOUNG ADULT;

EID: 84896709238     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26611     Document Type: Article

References (18)

1. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl. J Med. 2010;362:1071-1081.
2. Cordoba J, Minguez B. Hepatic encephalopathy. Semin Liver Dis 2008;28:70-80.
3. Mullen KD, Ferenci P, Bass NM, Leevy CV, Keeffe EB. An algorithm for the management of hepatic encephalopathy. Semin Liver Dis 2007;27(Suppl 2):32-48.
4. Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003;114:188-193.
5. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002;35:716-721.
6. Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: ISHEN consensus. Hepatology 2013 Mar 7. doi: 10.1002/hep.26370.
7. Bajaj JS, Cordoba J, Mullen KD, Amodia P, Shawcross DL, Butterworth RF, Morgan MY. Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharm Ther 2011;33:739-747.
8. Dam G, Keiding S, Munk OL, Ott, P, Vilstrup H, Bak LK, et al. Hepatic encephalopathy is associated with decreased cerebral oxygen metabolism and blood flow but not increased ammonia update. Hepatology 2013;57:258-265.
9. Sanyal A, Bass N, Poordad F, Sheikh MY, Mullen K, Sigal S, et al. Rifaximin decreases venous ammonia concentrations and time-weighted average ammonia concentrations correlate with overt hepatic encephalopathy (HE) as assessed by Conn score in a 6-month study. J Hepatol 2010;52:S84.
10. Lee B, Rhead W, Diaz GA, Scharschmidt BF, Mian A, Shchelochkov O, et al. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics, and ammonia control. Mol Genet Metab 2010;100:221-228.
11. McGuire BM, Zupanets I, Lowe ME, Syplyviy V, Monteleone J, Gargosky S, et al. Pharmacology and safety of a novel ammonia lowering agents in healthy adults and adults with cirrhosis. Hepatology 2010;51:2077-2085.
12. Lichter-Konecki U, Diaz GA, Merritt JL 2nd, Feigenbaum A, Jomphe C, Marier JF, et al. Ammonia (NH3) control in children with urea cycle disorders (UCDs); comparison of sodium phenylbutyrate and glycerol phenylbutyrate. Mol Genet Metab 2011;103:323-329.
13. Diaz GA, Krivitzky L, Mokhtarani M, Rhead W, Bartley J, Feigenbaum A, et al. Ammonia (NH3) control and improved neurcognitive outcome among urea cycle disorder (UCD) patients treated with glycerol phenylbutyrate (GPB). Hepatology 2013;57:2171-2179.
14. Smith W, Diaz GA, Lichter-Konecki U, Berry SA, Harding CO, McCandless SE, et al. Ammonia control in children ages 2 months through 5 years with urea cycle disorders (UCDs); Comparison of sodium phenylbutyrate and glycerol phenylbutyrate. J Pediatr 2013;162:1228-1234.
15. Ghabril M, Zupanets I, Vierling J, Mantry P, Rockey D, Wolf D, et al. Glycerol phenylbutyrate in patients with cirrhosis and episodic hepatic encephalopathy: a pilot study of safety and effect on venous ammonia concentration. Clin Pharmacol Drug Devp 2013;2:213-222.
16. Ortiz M, Cordoba J, Dovals E, Jacas C, Pujadas F, Esteban R, Guardia EJ. Development of a clinical hepatic encephalopathy staging scale. Aliment Pharmacol Ther 2007;26:859-867.
17. Thibault A, Cooper M, Figg W, Venzon DJ, Sartor O, Tompkins AC, et al. Phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 1994;54:1690-1694.
18. Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, et al. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer Res 1995;75:2932-2938.